ReviewCancer immunology, immunotherapy : CII2023

Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents.

Maria Livia Del Giudice et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.